Alectinib Superior to Crizotinib for ALK+ NSCLC [News in Brief]

Next-generation ALK inhibitor more than doubles progression-free survival, reduces brain and CNS metastases.

from Cancer via ola Kala on Inoreader http://ift.tt/2t4PcDN
via IFTTT